Acute Myeloid Leukemia Market to Exhibit Promising Growth at a 22% CAGR Fueled by Increasing Incidence and Imminent Launches of the Novel Therapies During the Study Period [2018-2030], States DelveInsight
The Acute Myeloid Leukemia market has a promising outlook with less toxic emerging therapies in development for the elderly patients, which traditionally have been considered to have higher relapse rates
LAS VEGAS, July 13, 2021 /PRNewswire/ -- DelveInsight's "Acute Myeloid Leukemia (AML) Market" report provides a thorough comprehension of the Acute Myeloid Leukemia historical and forecasted epidemiology and the Acute Myeloid Leukemia market trends in the 7MM [the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan]. The Acute Myeloid Leukemia market report also proffers an analysis of the current Acute Myeloid Leukemia treatment algorithm/practice, market drivers, market barriers, and unmet medical needs.
The Acute Myeloid Leukemia Market will increase because of an upsurge in research and development, enriched understanding of the disease, increased AML incidence, and imminent launches of the drugs. However, the AML market growth might be hindered due to the high cost of therapy, toxic therapies, limitations in designing clinical trials, and low survival rates.
The AML treatment landscape has remained virtually unchanged for almost five decades. There have been recent approvals in frontline patient's intensive chemotherapy eligible patients such as VYXEOS (Jazz Pharmaceuticals), RYDAPT (Novartis), MYLOTARG (Pfizer), and ONUREG (BMS), and in ineligible patients Daurismo (Pfizer), TIBSOVO (Agios Pharma), and VENCLEXTA (Abbvie). Approvals relapsed/refractory and salvage settings include IDHIFA (BMS), XOSPATA (Astellas Pharma), and the recent approval of VANFLYTA (Daiichi Sankyo).
Despite the new therapies, there are several limitations associated with the current milieu of drugs. The high relapse rate in the high-risk population remains a significant concern. The overall survival in the elderly population remains relatively low.
Various new therapies are in development with a focus on mentioned limitations of the currently approved drugs. Some of the most prominent ones include ASTX 727 (Astex Pharmaceutical), CPI-613 (Rafael Pharmaceuticals), CX-01 (Chimerix), APL-106 (GlycoMimetics Incorporated), Quizartinib (Daiichi Sankyo), MLN-4924 (Millennium Pharmaceuticals), Iomab-B (Actinium Pharmaceuticals), SLS-001 (Sellas Life Sciences), ARO-002 (Arog Pharmaceuticals), MGD-006 (MacroGenics), FT-2102 (Forma Therapeutics), DF9-10917 (Delta-Fly Pharma) and SNDX-5613 (Syndax Pharmaceuticals).
Acute Myeloid Leukemia (AML), also known as acute myelocytic leukemia, acute myelogenous leukemia, acute granulocytic leukemia, and acute non-lymphocytic leukemia, is a heterogeneous hematologic malignancy characterized by the clonal expansion of myeloid blasts in the peripheral blood, bone marrow, and/or other tissues.
DelveInsight estimates that the total Acute Myeloid Leukemia incidencein the 7MM was estimated to be 42,301 cases in 2021. Also, the males appear to have a predisposition to AML, so a higher percentage of patients was observed in males than females.
Treatment of most Acute Myeloid Leukemia patients typically consists of two chemotherapy (chemo) phases: remission induction (induction) and consolidation (postremission therapy).
If the patients are not cured with the induction treatment, then a second, similar course of chemotherapy called reinduction can be tried. If this is also not helpful, treatment with other chemo drugs or more intensive chemo may be tried. A stem cell transplant may be an option for some patients. If the patients are still not cured, they may consider taking part in a clinical trial of newer treatments.
Although the Acute Myeloid Leukemia treatment arena is quite active and various trials are underway to treat patients, continuous efforts are further needed to develop novel drugs which would be more effective and less toxic. Along with that, support from the government and industry support are also necessary.
TheAML markethas a promising outlook with emerging therapies. Various new therapies are in development, and some of the most prominent ones include ASTX 727, CPI-613, CX-01, APL-106, Quizartinib, MLN-4924, Iomab-B, SLS-001, ARO-002, MGD-006, FT-2102, DF9-10917, and SNDX-5613.
Despite the new therapies, there are several limitations associated with the current milieu of drugs. The high relapse rate in the high-risk population remains a significant concern. The overall survival in the elderly population remains relatively low. The multitude of chromosomal and genetic abnormalities makes the AML treatment a challenging prospect as the heterogeneous nature of disease renders targeted agents vulnerable. The intensive chemotherapy treatments used for the indication have serious side effects that many older patients cannot tolerate.
To conclude, the Acute Myeloid Leukemia Market will escalate since there has been advancing progress in understanding the genomic, proteomic, and metabolomic alterations of disease. The possibility of developing personalized therapy with improved clinical benefits is growing. Also, the incidence of Acute Myeloid Leukemia tends to increase over some time. Moreover, there has been a dramatic increase in much-needed research, including the approval of several products and ongoing clinical investigations for future therapies. The introduction of new drugs and increased access to therapies is expected to drive Acute Myeloid Leukemia market growth. The approval of novel therapies will serve a much larger patient pool and have demonstrated improved response in their target populations in several pivotal clinical trials, with some also demonstrated improved overall survival.
DelveInsight's Acute Myeloid Leukemia (AML) - Epidemiology Forecast 2030 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of Acute Myeloid Leukemia (AML) in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
Acute Myeloid Leukemia (AML) Pipeline Insights, 2021 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Acute Myeloid Leukemia Pipeline landscape. BioSight, GlycoMimetics, Novartis, Takeda, Menarini Group, ImmunoGen are some of the key pharmaceutical companies developing therapies for the Acute Myeloid Leukemia Pipeline.
DelveInsight's Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) - Epidemiology Forecast 2030 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
DelveInsight's Bipolar Disorder (Manic Depression) Market Insights, Epidemiology and Market Forecast - 2030 report provides a detailed overview of the disease and a depth understanding of the disease. Intra-Cellular Therapies, NeuroRx, Lundbeck, Otsuka Pharmaceutical, are involved in Bipolar Disorder drug development.
DelveInsight's Palmar Hyperhidrosis - Market Insights, Epidemiology, and Market Forecast - 2030 report provides a depth understanding of historical and forecasted epidemiology. Notable companies such as Atacama Therapeutics, Dermira, Inc. are developing Palmar Hyperhidrosis therapies.
DelveInsight's Glioblastoma multiforme (GBM) - Market Insights, Epidemiology and Market Forecast - 2030 report provides a detailed overview of the disease and a depth understanding of historical and forecasted epidemiology. Kye companies involved are VBL Therapeutics, Diffusion Pharmaceuticals, Bayer, Karyopharm Therapeutics, Aivita Biomedical, and others.
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also provides Business Consulting Serviceswith a credible market analysis that will help accelerate the business growth and overcome challenges with a practical approach.